Peritumoral Delivery of Docetaxel-TIPS Microparticles for Prostate Cancer Adjuvant Therapy.
adjuvant chemotherapy
docetaxel
microparticles
positive resection margin
prostate cancer
radical prostatectomy
Journal
Advanced therapeutics
ISSN: 2366-3987
Titre abrégé: Adv Ther (Weinh)
Pays: Germany
ID NLM: 101724632
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
11
08
2020
revised:
05
10
2020
entrez:
16
9
2021
pubmed:
17
9
2021
medline:
17
9
2021
Statut:
ppublish
Résumé
Recurrence of prostate cancer after radical prostatectomy is a consequence of incomplete tumor resection. Systemic chemotherapy after surgery is associated with significant toxicity. Improved delivery methods for toxic drugs capable of targeting positive resection margins can reduce tumor recurrence and avoid their known toxicity. This study evaluates the effectiveness and toxicity of docetaxel (DTX) release from highly porous biodegradable microparticles intended for delivery into the tissue cavity created during radical prostatectomy to target residual tumor cells. The microparticles, composed of poly(dl-lactide-
Identifiants
pubmed: 34527807
doi: 10.1002/adtp.202000179
pii: ADTP202000179
pmc: PMC8427470
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2000179Subventions
Organisme : British Heart Foundation
ID : FS/15/33/31608
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R026416/1
Pays : United Kingdom
Informations de copyright
© 2020 The Authors. Advanced Therapeutics published by Wiley‐VCH GmbH.
Déclaration de conflit d'intérêts
A patent application has been submitted by UCL Business covering the combination of DTX and TIPS microspheres.
Références
Acta Pharm Sin B. 2018 Jul;8(4):518-529
pubmed: 30109177
BMC Cancer. 2017 Jun 29;17(1):454
pubmed: 28662644
Biomaterials. 2013 Nov;34(33):8424-9
pubmed: 23899444
Yonsei Med J. 2016 Sep;57(5):1145-51
pubmed: 27401645
Nanomedicine. 2013 Jul;9(5):686-93
pubmed: 23219874
Tissue Eng Part C Methods. 2010 Oct;16(5):855-64
pubmed: 19886803
J Urol. 2013 Aug;190(2):441-9
pubmed: 23707439
Int J Pharm. 2017 Apr 30;522(1-2):119-127
pubmed: 28232270
Adv Ther. 2018 Jun;35(6):754-767
pubmed: 29796927
CA Cancer J Clin. 2019 Sep;69(5):363-385
pubmed: 31184787
J Hematol Oncol. 2014 Mar 05;7:20
pubmed: 24598155
Invest New Drugs. 1996;14(2):147-51
pubmed: 8913835
Sci Rep. 2018 Apr 9;8(1):5686
pubmed: 29632347
Drug Deliv. 2019 Dec;26(1):1115-1124
pubmed: 31735095
Cancer Sci. 2015 May;106(5):497-504
pubmed: 25728850
BMC Biotechnol. 2013 Nov 12;13:98
pubmed: 24215295
Investig Clin Urol. 2017 May;58(3):152-163
pubmed: 28480340
Urology. 2004 Jun;63(6):1138-42
pubmed: 15183967
Aliment Pharmacol Ther. 2008 Sep 1;28(5):614-22
pubmed: 18565160
Nat Protoc. 2006;1(1):241-5
pubmed: 17406239
Expert Opin Drug Deliv. 2012 Aug;9(8):975-90
pubmed: 22703284
Am J Mens Health. 2018 Nov;12(6):1807-1823
pubmed: 30203706
Cancer Treat Rev. 2003 Oct;29(5):407-15
pubmed: 12972359
Annu Rev Med. 2019 Jan 27;70:479-499
pubmed: 30691365
Trends Pharmacol Sci. 2016 Jun;37(6):451-462
pubmed: 27068431
BJU Int. 2010 Jul;106(1):37-43
pubmed: 20002667